10. Baek, S. Y. et al. Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA Trial. J. Clin. Oncol. 41, 4864–...
ER-Positive Breast Cancer: Chemotherapy Plus Tamoxifen Extends SurvivalAn abstract is unavailable.doi:10.1097/01.COT.0000287844.29669.86Susman, EdOncology Times
CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhibitors is inevitable. To address this challenge, novel strategies are required to overcome res...
4. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009; 116(1): 53- 68. 审批号:CN-114110 有效期至:2024-...
Sacituzumab govitecan(Trodelvy) is a monoclonal antibody with an attached chemotherapy drug. It is used to treat some advanced HR+, HER2-negative breast cancer. Learn more abouthormone therapy to treat breast cancer. HER2-Positive Breast Cancer ...
4. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009; 116(1): 53- 68. 审批号:CN-114110 有效期至:2024-4-28 声明:本材料由阿斯利康支持,仅供医疗卫生专业人士参考...
Chemotherapy with dual HER2-targeting agents (e.g., pertuzumab, trastuzumab) is considered optimal neoadjuvant therapy for patients with operable W Gradishar - 《Nejm Journal Watch》 被引量: 0发表: 2021年 Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer Neoadjuvant end...
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer The 21-gene recurrence score (RS) assay evaluates the likelihood of distant recurrence and benefit of chemotherapy in lymph node-negative, estrogen recepto... G Turashvili,JF Chou,E...
21-gene assay to inform chemotherapy benefit in node-positive breast cancer. New Engl J Med. 2021;385:2336–47 This very important study has shown no adjuvant chemoendocrine therapy benefit over endocrine therapy alone in postmenopausal patients with 1-3 positive lymph nodes and Recurrence Score ...
[2] 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet, 2007, 369(9555): 29-36. [3] 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the...